- Home
- HSPO vs FATE Comparison
HSPO vs FATE Comparison
Compare HSPO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- FATE
- Stock Information
- Founded
- HSPO 2014
- FATE 2007
- Country
- HSPO United States
- FATE United States
- Employees
- HSPO N/A
- FATE N/A
- Industry
- HSPO Blank Checks
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSPO Finance
- FATE Health Care
- Exchange
- HSPO Nasdaq
- FATE Nasdaq
- Market Cap
- HSPO 49.4M
- FATE 152.4M
- IPO Year
- HSPO 2022
- FATE 2013
- Fundamental
- Price
- HSPO $11.79
- FATE $1.03
- Analyst Decision
- HSPO
- FATE Hold
- Analyst Count
- HSPO 0
- FATE 8
- Target Price
- HSPO N/A
- FATE $5.43
- AVG Volume (30 Days)
- HSPO 294.0
- FATE 2.1M
- Earning Date
- HSPO 01-01-0001
- FATE 05-12-2025
- Dividend Yield
- HSPO N/A
- FATE N/A
- EPS Growth
- HSPO N/A
- FATE N/A
- EPS
- HSPO 0.27
- FATE N/A
- Revenue
- HSPO N/A
- FATE $13,631,000.00
- Revenue This Year
- HSPO N/A
- FATE N/A
- Revenue Next Year
- HSPO N/A
- FATE N/A
- P/E Ratio
- HSPO $44.35
- FATE N/A
- Revenue Growth
- HSPO N/A
- FATE N/A
- 52 Week Low
- HSPO $10.87
- FATE $0.66
- 52 Week High
- HSPO $12.41
- FATE $5.92
- Technical
- Relative Strength Index (RSI)
- HSPO 46.31
- FATE 46.14
- Support Level
- HSPO $11.78
- FATE $0.91
- Resistance Level
- HSPO $11.90
- FATE $1.34
- Average True Range (ATR)
- HSPO 0.02
- FATE 0.15
- MACD
- HSPO -0.02
- FATE -0.03
- Stochastic Oscillator
- HSPO 4.76
- FATE 20.69
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.